Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results

Article Abstract:

Women with breast cancer that has spread to more than three lymph nodes in the armpit may have a higher survival rate if they are treated with doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil (CMF) rather than alternating doses of these agents. Researchers administered combination chemotherapy to 403 women with breast cancer after the patients had mastectomies or breast conservation surgeries. Half of the women received four courses of intravenous doxorubicin followed by eight courses of intravenous CMF. The other women received two courses of intravenous CMF and one course of doxorubicin for a total of 12 cycles. At the ten-year follow-up, relapse-free survival was 42% in women treated with doxorubicin and CMF sequentially and 28% in women treated with alternating doses of doxorubicin and CMF. The total survival rate was 58% in women treated with sequential chemotherapy and 44% in women who received alternating chemotherapy.

Health aspects, Dosage and administration, Chemotherapy, Combination, Combination chemotherapy, Doxorubicin

---

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

Article Abstract:

Treating breast cancer patients with cyclophosphamide, methotrexate and fluorouracil after mastectomy may prolong survival. Of 386 women with breast cancer treated with a radical mastectomy, 207 received 12 monthly treatments of cyclophosphamide, methotrexate and fluorouracil and 179 received no further treatment (the control group). After 20 years, those who received the chemotherapy had survived a median of 137 months, while those in the control group survived a median of 104 months. Women whose cancer had affected few underarm lymph nodes benefitted most from the chemotherapy, but postmenopausal women benefitted least. In fact, lymph node involvement, chemotherapy and menopausal status were the most important factors determining prolonged survival. Postmenopausal women may not have received high enough doses of the drugs.

Mastectomy

---

High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma

Article Abstract:

High-dose sequential chemotherapy appears to be more effective than MACOP-B in patients with B-cell lymphoma. Researchers studied 98 patients with this type of lymphoma, 48 of whom received high-dose sequential chemotherapy and 50 of whom received MACOP-B followed by a bone marrow transplant. The high-dose chemotherapy consisted of doxorubicin, prednisone, vincristine, cyclophosphamide, methotrexate and etoposide. Patients in this group were more likely to respond completely, have lower relapse rates and increased survival rates.

Bone marrow, Bone marrow transplantation, Lymphomas, Chemotherapy

Similar abstracts:

• Abstracts: Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials
• Abstracts: ]omparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection
• Abstracts: Reduction in the incidence of human listeriosis in the United States: effectiveness of prevention efforts? Serogroup C meningococcal outbreaks in the United States: an emerging threat
• Abstracts: A special brand of know-how. AMA '97 legislative agenda speaks for you
• Abstracts: Thinking about a career change? Take it step by step. AMA cos-sponsoring computer courses. What's next?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.